Literature DB >> 30705123

Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Lakmali Munasinghage Silva1, Thomas Kryza2, Thomas Stoll3, Christine Hoogland3, Ying Dong2, Carson Ryan Stephens2, Marcus Lachlan Hastie3, Viktor Magdolen4, Oded Kleifeld5, Jeffrey John Gorman3, Judith Ann Clements6.   

Abstract

Kallikrein-related peptidase 7 (KLK7) is a serine peptidase that is over expressed in ovarian cancer. In vitro functional analyses have suggested KLK7 to play a cancer progressive role, although monitoring of KLK7 expression has suggested a contradictory protective role for KLK7 in ovarian cancer patients. In order to help delineate its mechanism of action and thereby the functional roles, information on its substrate repertoire is crucial. Therefore, in this study a quantitative proteomics approach-PROtein TOpography and Migration Analysis Platform (PROTOMAP)-coupled with SILAC was used for in-depth analysis of putative KLK7 substrates from a representative ovarian cancer cell line, SKOV-3, secreted proteins. The Terminal Amine Isotopic Labeling of Substrates (TAILS) approach was used to determine the exact cleavage sites and to validate qPROTOMAP-identified putative substrates. By employing these two technically divergent approaches, exact cleavage sites on 16 novel putative substrates and two established substrates, matrix metalloprotease (MMP) 2 and insulin growth factor binding protein 3 (IGFBP3), were identified in the SKOV-3 secretome. Eight of these substrates were also identified on TAILS analysis of another ovarian cancer cell (OVMZ-6) secretome, with a further seven OVMZ-6 substrates common to the SKOV-3 qPROTOMAP profile. Identified substrates were significantly associated with the common processes of cell adhesion, extracellular matrix remodeling and cell migration according to the gene ontology (GO) biological process analysis. Biochemical validation supports a role for KLK7 in directly activating pro-MMP10, hydrolysis of IGFBP6 and cleavage of thrombospondin 1 with generation of a potentially bioactive N-terminal fragment. Overall, this study constitutes the most comprehensive analysis of the putative KLK7 degradome in any cancer to date, thereby opening new avenues for KLK7 research.
© 2019 Silva et al.

Entities:  

Keywords:  Degradomics*; Extracellular matrix*; Kallikrein-related Peptidases; Ovarian cancer; Proteases*; Secretome; Substrate identification

Mesh:

Substances:

Year:  2019        PMID: 30705123      PMCID: PMC6495248          DOI: 10.1074/mcp.RA118.001304

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  56 in total

1.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

2.  Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.

Authors:  Panagiotis Prezas; Matthias J E Arlt; Petar Viktorov; Antoninus Soosaipillai; Leon Holzscheiter; Manfred Schmitt; Maroulio Talieri; Eleftherios P Diamandis; Achim Krüger; Viktor Magdolen
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

3.  In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.

Authors:  Ankit Sinha; Vladimir Ignatchenko; Alex Ignatchenko; Salvador Mejia-Guerrero; Thomas Kislinger
Journal:  Biochem Biophys Res Commun       Date:  2014-01-14       Impact factor: 3.575

4.  Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains.

Authors:  Vishnu C Ramani; Gur P Kaushal; Randy S Haun
Journal:  Biochim Biophys Acta       Date:  2011-05-17

5.  Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products.

Authors:  Oded Kleifeld; Alain Doucet; Ulrich auf dem Keller; Anna Prudova; Oliver Schilling; Rajesh K Kainthan; Amanda E Starr; Leonard J Foster; Jayachandran N Kizhakkedathu; Christopher M Overall
Journal:  Nat Biotechnol       Date:  2010-03-07       Impact factor: 54.908

6.  Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.

Authors:  A A Alvarez; J R Axelrod; R S Whitaker; P D Isner; R C Bentley; R K Dodge; G C Rodriguez
Journal:  Gynecol Oncol       Date:  2001-08       Impact factor: 5.482

7.  Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment.

Authors:  S Rabhi-Sabile; D Pidard; J Lawler; P Renesto; M Chignard; C Legrand
Journal:  FEBS Lett       Date:  1996-05-13       Impact factor: 4.124

8.  Global mapping of the topography and magnitude of proteolytic events in apoptosis.

Authors:  Melissa M Dix; Gabriel M Simon; Benjamin F Cravatt
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

9.  A uniform proteomics MS/MS analysis platform utilizing open XML file formats.

Authors:  Andrew Keller; Jimmy Eng; Ning Zhang; Xiao-jun Li; Ruedi Aebersold
Journal:  Mol Syst Biol       Date:  2005-08-02       Impact factor: 11.429

10.  ProteomeXchange provides globally coordinated proteomics data submission and dissemination.

Authors:  Juan A Vizcaíno; Eric W Deutsch; Rui Wang; Attila Csordas; Florian Reisinger; Daniel Ríos; José A Dianes; Zhi Sun; Terry Farrah; Nuno Bandeira; Pierre-Alain Binz; Ioannis Xenarios; Martin Eisenacher; Gerhard Mayer; Laurent Gatto; Alex Campos; Robert J Chalkley; Hans-Joachim Kraus; Juan Pablo Albar; Salvador Martinez-Bartolomé; Rolf Apweiler; Gilbert S Omenn; Lennart Martens; Andrew R Jones; Henning Hermjakob
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

View more
  7 in total

1.  The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.

Authors:  Thomas Kryza; Nathalie Bock; Scott Lovell; Anja Rockstroh; Melanie L Lehman; Adam Lesner; Janaththani Panchadsaram; Lakmali Munasinghage Silva; Srilakshmi Srinivasan; Cameron E Snell; Elizabeth D Williams; Ladan Fazli; Martin Gleave; Jyotsna Batra; Colleen Nelson; Edward W Tate; Jonathan Harris; John D Hooper; Judith A Clements
Journal:  Mol Oncol       Date:  2019-11-28       Impact factor: 6.603

2.  Analysis of expression and prognosis of KLK7 in ovarian cancer.

Authors:  Erhua Chen; Huifang Zhu; Yue Yang; Ling Wang; Jianhua Zhang; Yonghong Han; Xiang Liu
Journal:  Open Med (Wars)       Date:  2020-09-30

3.  Protein cleavage influences surface protein presentation in Mycoplasma pneumoniae.

Authors:  Iain J Berry; Michael Widjaja; Veronica M Jarocki; Joel R Steele; Matthew P Padula; Steven P Djordjevic
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

4.  Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers.

Authors:  Stavroula L Kastora; Georgios Kounidas; Valerie Speirs; Yazan A Masannat
Journal:  Cancers (Basel)       Date:  2022-08-09       Impact factor: 6.575

5.  Effects of Laparoscopic Hyperthermic Perfusion Therapy Combined with Adjuvant Treatment of Compound Yew Capsule on Ovarian Blood Flow Parameters and Immune Function in Patients with Ovarian Cancer.

Authors:  Mengya Su; Donghui Wang; Ping Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

6.  Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Weiwei Gong; Yueyang Liu; Eleftherios P Diamandis; Marion Kiechle; Holger Bronger; Julia Dorn; Tobias Dreyer; Viktor Magdolen
Journal:  J Ovarian Res       Date:  2020-10-21       Impact factor: 4.234

7.  Cytoskeletal protein degradation in brain death donor kidneys associates with adverse posttransplant outcomes.

Authors:  Rebecca H Vaughan; Jean-Claude Kresse; Louise K Farmer; Marie L Thézénas; Benedikt M Kessler; Jan H N Lindeman; Edward J Sharples; Gavin I Welsh; Rikke Nørregaard; Rutger J Ploeg; Maria Kaisar
Journal:  Am J Transplant       Date:  2022-02-04       Impact factor: 9.369

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.